Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update

Core Insights - Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has experienced a significant decline in share price, down nearly 64% over the past year, but has recently stabilized with a 7.19% gain over the last five trading sessions [2] - The company is advancing its lead gene therapy program, seeking accelerated approval for isaralgagene civaparvovec (ST-920) for adults with Fabry disease through a rolling Biologics License Application (BLA) submission to the FDA [3] - The STAAR study data supports the BLA, indicating that ST-920 may serve as a one-time, durable gene therapy, with the FDA validating the use of mean annualized eGFR slope at 52 weeks as an accelerated approval endpoint [4] Company Overview - Sangamo Therapeutics is a clinical-stage biotech company focused on developing genomic medicines for inherited metabolic, neurologic, and immune diseases, utilizing gene therapy and genome engineering platforms [5]